# Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05963490/  
OnCo record `nct05963490` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib and toripalimab in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05963490 by Fudan University, with a registry enrolment figure of 108 participants, started 2023-04-25 and due to reach its primary completion in 2025-04-25. Interventions recorded: Regorafenib; Toripalimab; Radiotherapy; Regorafenib. Conditions listed: Microsatellite Stable Metastatic Colorectal Cancer. Primary outcome: OS. Colorectal eligibility wording from the registry: "Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SLOT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05963490
- Phase: 2
- Setting: A Prospective, Randomized, Controlled Phase II Trial of Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab as Third-line Treatment in Patients With Metastatic Colorectal Cancer
- Sponsor: Fudan University
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT05963490: https://clinicaltrials.gov/study/NCT05963490

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05963490.json